Topical delivery of hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior & posterior segments of the eye

Drug Delivery Technology

Volumn 10, Issue 4, 2010, Pages 42-47

  Velagaleti, Poonam R ^a   Anglade, Eddy ^b   Khan, I John ^b   Gilger, Brian C ^c   Mitra, Ashim K ^d  

^a Lux BioSciences   (United States)

^b Lux Biosciences Inc   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; LX 214; PLACEBO; UNCLASSIFIED DRUG; VOCLOSPORIN;

ANTERIOR EYE SEGMENT; AQUEOUS SOLUTION; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; DOG; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; EMULSION; EYE DISEASE; FOOD AND DRUG ADMINISTRATION; HELPER CELL; HUMAN; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS SICCA; MICELLE; NANOTECHNOLOGY; NONHUMAN; ORGAN TRANSPLANTATION; RABBIT; SHORT SURVEY; TOPICAL DRUG ADMINISTRATION; UVEITIS;

EID: 77952271193     PISSN: 15372898     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Short Survey

References (16)

1. Booth BA, Denham LV, Bouhanik S, Jacob JT, Hill JM. Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. Drugs Aging. 2007;24:581-602. (Pubitemid 47195677)
2. del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today. 2008;13:135-143.
3. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57:2010-2032. (Pubitemid 41740793)
4. Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28:473-493.
5. Koevary SB. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metab. 2003;4:213-222.
6. Mainardes RM, Urban MCC, Cinto PO, Khalil NM, Chaud MV, Evangelista RC, Gremiao MPD. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets. 2005;6:363-371. (Pubitemid 40667801)
7. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58:1136-1163.
8. Granelli-Piperno A, Andrus L, Steinman RM. Lymphokine and nonlymphokine mRNA levels in stimulated human cells: kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med. 1986;163:922-937. (Pubitemid 16082807)
9. Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Reviews in Molecular Medicine. 2000;2(4):1-23.
10. Anglade E, Yatscoff R, Foster R, Grau U. Next-generation calcineurin inhibitors for ophthalmic indications. Expert Opinion on Investigational Drugs. 2007;16:1525-1540.
11. Hackett RB, McDonald TO. Ophthalmic Toxicology and Assessing Ocular Irritation. In: Marzulli FN, Maibach HI, eds. Dermatoxicology, 5th Edition. Washington, DC: Hemisphere Publishing Corporation;1996:299-305,557-566.
12. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol. 2002;47(Suppl 1):S41-S52.
13. Loftsson T, Sigurdsson HH, Konradsdottir F, Gisladottir S, Jansook P, Stefansson E. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie. 2008;63(3):171-179. (Pubitemid 351449926)
14. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24(1):1-16.
15. Komai Y, Ushiki T. The three-dimensional organization of collagen fibrils in the human cornea and sclera. Invest Ophthalmol Vis Sci. 1991;32(8):2244- 2258.
16. Hu X, Jing X. Biodegradable amphiphilic polymer-drug conjugate micelles. Expert Opin Drug Delivery. 2009;6(10):1079-1090.